Denosumab for the treatment of osteoporosis and cancer-related conditions

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 1, 2012, Pages 123-133

  Lewiecki, E M ^a   Bilezikian, J P ^b  

^a New Mexico Clinical Research Osteoporosis Center   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; ESTROGEN; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CELLULITIS; CHILL; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FEVER; FRACTURE; HEALTH PROGRAM; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPOCALCEMIA; INFECTION; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SKELETAL RELATED EVENT; SOLID TUMOR; STROKE; VERTEBRA FRACTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; TREATMENT OUTCOME;

EID: 84055169866     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.268     Document Type: Review

References (64)

1. Klibanski, A. et al. Osteoporosis prevention, diagnosis, and therapy. JAMA. 285, 785-795 (2001). (Pubitemid 32167238)
2. Melton, L.J. 3rd, Chrischilles, E.A., Cooper, C., Lane, A.W. & Riggs, B.L. Perspective. How many women have osteoporosis? J. Bone Miner. Res. 7, 1005-1010 (1992).
3. Center, J.R., Nguyen, T.V., Schneider, D., Sambrook, P.N. & Eisman, J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353, 878-882 (1999). (Pubitemid 29126875)
4. Cooper, C. The crippling consequences of fractures and their impact on quality of life. Am. J. Med. 103, 12S-17S; discussion 17S (1997).
5. Curtis, J.R., Westfall, A.O., Cheng, H., Lyles, K., Saag, K.G. & Delzell, E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J. Bone Miner. Res. 23, 1435-1441 (2008).
6. Foley, K.A., Foster, S.A., Meadows, E.S., Baser, O. & Long, S.R. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med. Care 45, 902-906 (2007).
7. McCombs, J.S., Thiebaud, P., McLaughlin-Miley, C. & Shi, J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48, 271-287 (2004). (Pubitemid 38781153)
8. Caro, J.J., Ishak, K.J., Huybrechts, K.F., Raggio, G. & Naujoks, C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos. Int. 15, 1003-1008 (2004). (Pubitemid 40064656)
9. Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046-1060 (2011).
10. Roodman, G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664 (2004).
11. Mundy, G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593 (2002). (Pubitemid 37328925)
12. Guise, T.A. The vicious cycle of bone metastases. J. Musculoskelet. Neuronal Interact. 2, 570-572 (2002). (Pubitemid 36157607)
13. Penning-van Beest, F.J., Goettsch, W.G., Erkens, J.A. & Herings, R.M. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin. Ther. 28, 236-242 (2006). (Pubitemid 44287822)
14. Gordon, S. et al. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br. J. Haematol. 119, 475-483 (2002). (Pubitemid 35365501)
15. Rosen, L.S. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7, 377-387 (2001). (Pubitemid 33759002)
16. Rosen, L.S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100, 2613-2621 (2004). (Pubitemid 38715767)
17. Saad, F. et al.; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 94, 1458-1468 (2002).
18. Collin-Osdoby, P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ. Res. 95, 1046-1057 (2004). (Pubitemid 39557891)
19. Hsu, H. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96, 3540-3545 (1999). (Pubitemid 29168945)
20. Lacey, D.L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998). (Pubitemid 28180851)
21. Simonet, W.S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997). (Pubitemid 27199902)
22. Burgess, T.L. et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538 (1999). (Pubitemid 29215717)
23. Mosekilde, L., Søgaard, C.H., Danielsen, C.C. & Tørring, O. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology 129, 421-428 (1991).
24. Lacey, D.L. et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 157, 435-448 (2000). (Pubitemid 30626907)
25. Hofbauer, L.C. & Schoppet, M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292, 490-495 (2004). (Pubitemid 38988958)
26. Boyle, W.J., Simonet, W.S. & Lacey, D.L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003). (Pubitemid 40852708)
27. Bekker, P.J. et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066 (2004). (Pubitemid 41110556)
28. Miller, P.D. et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J. Clin. Endocrinol. Metab. 96, 394-402 (2011).
29. Miller, P.D. et al.; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43, 222-229 (2008).
30. Lewiecki, E.M. et al.; AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J. Bone Miner. Res. 22, 1832-1841 (2007). (Pubitemid 351229299)
31. McClung, M.R. et al.; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821-831 (2006). (Pubitemid 43290920)
32. McClung, M. et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. J. Bone Miner. Res. 26(Suppl 1):S20 (2011).
33. Cummings, S.R. et al.; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009).
34. Bone, H.G. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93, 2149-2157 (2008). (Pubitemid 351831529)
35. Brown, J.P. et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J. Bone Miner. Res. 24, 153-161 (2009).
36. Kendler, D.L. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone Miner. Res. 25, 72-81 (2010).
37. Smith, M.R. et al.; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745-755 (2009).
38. Eastell, R. et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J. Clin. Oncol. 26, 1051-1057 (2008).
39. Vestergaard, P., Rejnmark, L. & Mosekilde, L. Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. Calcif. Tissue Int. 82, 334-340 (2008).
40. Ellis, G.K. et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26, 4875-4882 (2008).
41. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011).
42. Stopeck, A.T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139 (2010).
43. Henry, D.H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125-1132 (2011).
44. Bone, H.G. III et al. Denosumab treatment for 5 years of postmenopausal women with osteoporosis: results from the first two years of the FREEDOM trial extension. American Association of Clinical Endocrinologists 20th Annual Meeting and Clinical Congress, San Diego, CA, 13-17 April 2011. Abstract 503.
45. A mgen Inc. Xgeva [prescribing information]. 〈http://pi.amgen.com/ united-states/xgeva/xgeva-pi.pdf〉.
46. Jönsson, B. et al. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos. Int. 22, 967-982 (2011).
47. Clowes, J.A., Riggs, B.L. & Khosla, S. The role of the immune system in the pathophysiology of osteoporosis. Immunol. Rev. 208, 207-227 (2005). (Pubitemid 41746395)
48. Xing, L., Schwarz, E.M. & Boyce, B.F. Osteoclast precursors, RANKL/RANK, and immunology. Immunol. Rev. 208, 19-29 (2005).
49. Dougall, W.C. et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424 (1999). (Pubitemid 29453612)
50. Kong, Y.Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
51. Stolina, M. et al. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J. Immunol. 179, 7497-7505 (2007).
52. Stolina, M. et al. Rats and mice overexpressing soluble OPG have high bone mass but no alteration in immunological parameters or lymphocyte function. Arthritis Rheum. 20, S708 (2005).
53. US Food and Drug Administration and Amgen. Briefing Information for the August 13, 2009, Meeting of the Reproductive Health Drugs Advisory Committee 〈http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ReproductiveHealthDrugsAdvisoryCommittee/ucm176584.htm〉.
54. Reid, I.R. et al.; Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J. Bone Miner. Res. 25, 2256-2265 (2010).
55. Lewiecki, E.M. Treatment of osteoporosis with denosumab. Maturitas 66, 182-186 (2010).
56. Brown, J.P. et al. Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. J. Bone Miner. Res. (2011).
57. A mgen Inc. Amgen Medical Information 〈https://www.amgenmedinfo.com/ Home〉. Accessed 15 September 2011.
58. A mgen Inc. Prolia Postmarketing Active Safety Surveillance Program 〈https://proliasafety.secure.force.com/prolia〉. Accessed 26 August 2011.
59. US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program 〈http://www.fda.gov/Safety/MedWatch/ default.htm〉. Accessed 26 August 2011.
60. A mgen Inc. Prolia (denosumab) Risk Evaluation and Mitigation Strategy 〈http://www.proliahcp.com/risk-evaluation-mitigation-strategy/〉. Accessed 26 August 2011.
61. A mgen Inc. Prolia [prescribing Information] 〈http://pi.amgen.com/ united-states/prolia/prolia-pi.pdf〉.
62. A mgen Inc. Prolia Medication Guide 〈http://pi.amgen.com/united- states/prolia/prolia-mg.pdf〉.
63. A mgen Inc. Important drug warning regarding Prolia (denosumab) 〈http://www.proliahcp.com/pdf/dear-healthcare-professional-letter. pdf〉.
64. Lewiecki, E.M. Denosumab: a promising drug for the prevention and treatment of osteoporosis. Womens. Health (Lond. Engl). 2, 517-525 (2006). (Pubitemid 43984131)